Le Lézard
Classified in: Science and technology, Business
Subject: PDT

DeFi Lens builds advanced Generative AI for Technical Analysis


NEW YORK, April 23, 2024 /CNW/ -- In the dynamic world of decentralized finance (DeFi), staying ahead of the curve and maintaining a competitive edge is crucial. Today, it is thrilling to announce the launch of DeFi Lens (https://defilens.ai) ? an innovative AI platform combining generative AI and Web3 trustworthy proofs to equip traders, especially those using technical analysis (TA) strategies, and crypto enthusiasts with better market signals and insights. DeFi Lens transforms how traders or crypto users search for alphas, exchange signals & data, and analyze trading strategies. The project is incubated by Oraichain Labs.

Revolutionizing Crypto Analysis with AI

DeFi Lens combines popular analytics tools in the crypto market and the power of generative AI. DeFi Lens is a fusion of AI and Web3 to approach real-time market intelligence to facilitate a Web3 future that is more efficient, and accessible than ever before.

DeFi Lens has its key features to compete with other crypto tools in the market:

Join the DeFi Lens revolution

DeFi Lens launched its FREE public beta this April and is now available at https://defilens.ai. Explore this groundbreaking tool now, connect with its vibrant community, and take crypto journeys to new heights.

About DeFi Lens

Incubated by Labs, DeFi Lens is an AI crypto tool with customizable and generative power to transform how traders or crypto users search for alphas, exchange signals, and analyze trading strategies. Signals and strategies are subject to monetary values and follow a Trustworthy Proofs protocol.

About Oraichain

Oraichain (https://orai.io) provides multidimensional trustworthy proofs of AI and enables secure integration with Web3. Oraichain is the world's first layer 1 of AI oracle.

Media Contact: DeFi Lens, [email protected]

SOURCE DeFi Lens


These press releases may also interest you

at 16:05
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended March 31, 2024. First...

at 16:05
Harrow , a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the "Investors" section of...

at 16:05
CVD Equipment Corporation , today announced its financial results for the first quarter ended March 31, 2024. Manny Lakios, President and CEO of CVD Equipment Corporation, commented, "First quarter 2024 revenue was $4.9 million, down significantly...

at 16:05
Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended...

at 16:05
Dundee Corporation ("Dundee") announced today that its board of directors has approved the payment of a quarterly cash dividend of $0.33025 per cumulative 5-year rate reset first preference share, series 2 payable on July 2, 2024 to shareholders of...

at 16:05
Dundee Corporation ("Dundee") announced today that its board of directors has approved the payment of a quarterly cash dividend of $0.56595 per cumulative floating rate first preference share, series 3 payable on July 2, 2024 to shareholders of...



News published on and distributed by: